Carla Abdelnour, PhD, Stanford University, Palo Alto, CA, talks on the lack of sufficient outcome measures to determine a drug’s efficacy, following a systematic review of randomized clinical trials in patients with dementia with Lewy bodies (DLB). The existing outcome measures include scores on the mini-mental state examination (MMSE), the cognitive dementia rating (CDR) and the modified body and soul-unified Parkinson’s disease rating scale (MBS-UBDRS). These are commonly used measures in Alzheimer’s and Parkinson’s disease clinical trials but may not be sensitive enough to detect changes in patients with DLB. Therefore, there is a need for DLB-specific outcome measures which are sensitive enough to detect changes to aid drug development. This interview took place at the Alzheimer’s Association International Conference (AAIC) 2023 in Amsterdam, Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
